CY1114419T1 - Παραγωγα συντηγμενου θειαζολιου ως αναστολεις κινασης - Google Patents

Παραγωγα συντηγμενου θειαζολιου ως αναστολεις κινασης

Info

Publication number
CY1114419T1
CY1114419T1 CY20131100552T CY131100552T CY1114419T1 CY 1114419 T1 CY1114419 T1 CY 1114419T1 CY 20131100552 T CY20131100552 T CY 20131100552T CY 131100552 T CY131100552 T CY 131100552T CY 1114419 T1 CY1114419 T1 CY 1114419T1
Authority
CY
Cyprus
Prior art keywords
thiazolium
synthesised
production
suspensions
moving
Prior art date
Application number
CY20131100552T
Other languages
Greek (el)
English (en)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile Crépy
Anne Marie Foley
Richard Jeremy Franklin
Original Assignee
Ucb Pharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by Ucb Pharma, S.A. filed Critical Ucb Pharma, S.A.
Publication of CY1114419T1 publication Critical patent/CY1114419T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20131100552T 2006-06-26 2013-07-03 Παραγωγα συντηγμενου θειαζολιου ως αναστολεις κινασης CY1114419T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
EP08775774A EP2170906B1 (en) 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1114419T1 true CY1114419T1 (el) 2016-08-31

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100552T CY1114419T1 (el) 2006-06-26 2013-07-03 Παραγωγα συντηγμενου θειαζολιου ως αναστολεις κινασης

Country Status (20)

Country Link
US (3) US8242116B2 (https=)
EP (2) EP2035436B1 (https=)
CN (1) CN101687885B (https=)
AT (1) ATE510840T1 (https=)
AU (1) AU2008269577B2 (https=)
CA (1) CA2692085C (https=)
CO (1) CO6270229A2 (https=)
CY (1) CY1114419T1 (https=)
DK (1) DK2170906T3 (https=)
EA (1) EA017187B1 (https=)
ES (2) ES2365258T3 (https=)
HR (1) HRP20130523T1 (https=)
IL (1) IL202659A0 (https=)
ME (1) ME01592B (https=)
MX (1) MX2009013740A (https=)
MY (1) MY148852A (https=)
PL (1) PL2170906T3 (https=)
PT (1) PT2170906E (https=)
RS (1) RS52824B (https=)
WO (1) WO2008001076A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
WO2010011871A2 (en) * 2008-07-23 2010-01-28 The Regents Of The University Of California Methods and compositions for providing salicylic acid-independent pathogen resistance in plants
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
CA2752596A1 (en) 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
US20120022057A1 (en) * 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US8410095B2 (en) 2009-05-20 2013-04-02 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
IN2012DN01325A (https=) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
CA2782950A1 (en) 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
KR20120101551A (ko) * 2009-12-18 2012-09-13 얀센 파마슈티카 엔.브이. Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
JP6025717B2 (ja) 2010-06-15 2016-11-16 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 新規なオルト置換されたアリールアミド誘導体
BR112013007056A2 (pt) 2010-10-01 2019-09-24 Basf Se compostos de imina
TW201307309A (zh) * 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
AU2011332859A1 (en) * 2010-11-24 2013-06-20 Exelixis, Inc. Benzoxazepines as inhibitors of mTOR and methods of their use and manufacture
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
JP5903499B2 (ja) 2011-12-22 2016-04-13 ノバルティス アーゲー ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
PL2970132T3 (pl) 2013-03-14 2021-04-06 Epizyme, Inc. Inhibitory metylotransferazy argininy i ich zastosowania
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP6461942B2 (ja) * 2013-10-21 2019-01-30 ユミコア・アクチエンゲゼルシャフト・ウント・コムパニー・コマンディットゲゼルシャフトＵｍｉｃｏｒｅ ＡＧ ＆ Ｃｏ．ＫＧ 芳香族アミンのモノアリール化
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
WO2020056269A1 (en) 2018-09-13 2020-03-19 Stemline Therapeutics, Inc. Methods for treating centronuclear myopathy
BR112021010453A2 (pt) 2018-12-19 2021-08-24 Leo Pharma A/S Composto, e, composição farmacêutica
CA3125900A1 (en) * 2019-01-08 2020-07-16 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitor
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
AU2008269577A1 (en) 2008-12-31
MX2009013740A (es) 2010-02-01
ES2416364T3 (es) 2013-07-31
US8338592B2 (en) 2012-12-25
ES2365258T3 (es) 2011-09-27
EP2035436A1 (en) 2009-03-18
EP2170906A1 (en) 2010-04-07
CA2692085A1 (en) 2008-12-31
PL2170906T3 (pl) 2013-08-30
DK2170906T3 (da) 2013-06-24
EA017187B1 (ru) 2012-10-30
US8242116B2 (en) 2012-08-14
HRP20130523T1 (en) 2013-07-31
MY148852A (en) 2013-06-14
CN101687885B (zh) 2012-08-22
RS52824B (https=) 2013-10-31
US20130079330A1 (en) 2013-03-28
ME01592B (me) 2014-09-20
EP2035436B1 (en) 2011-05-25
AU2008269577B2 (en) 2012-12-20
IL202659A0 (en) 2010-06-30
WO2008001076A1 (en) 2008-01-03
EA201000038A1 (ru) 2010-06-30
CO6270229A2 (es) 2011-04-20
CA2692085C (en) 2015-10-13
US20110003785A1 (en) 2011-01-06
CN101687885A (zh) 2010-03-31
US20100137302A1 (en) 2010-06-03
ATE510840T1 (de) 2011-06-15
PT2170906E (pt) 2013-06-25
US8710054B2 (en) 2014-04-29
EP2170906B1 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CY1114419T1 (el) Παραγωγα συντηγμενου θειαζολιου ως αναστολεις κινασης
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
ATE526021T1 (de) Kondensierte thiazol-derivate als kinase-hemmer
WO2009081105A3 (en) Quinoxaline and quinoline derivatives as kinase inhibitors
WO2010052448A3 (en) Fused pyrazine derivatives as kinase inhibitors
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
EA202192170A1 (ru) ТИЕНО[3,2-b]ПИРИДИН-7-АМИНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ СЕМЕЙНОЙ ВЕГЕТО-СОСУДИСТОЙ ДИСТОНИИ
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
CL2008003280A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
HUE036953T2 (hu) 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
ZA201100437B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
WO2006098961A3 (en) Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы
WO2013142253A3 (en) TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES
DOP2009000289A (es) Derivados de tiazol fusionados como inhibidores de quinasa
PL2004670T3 (pl) Sposób wytwarzania pochodnych lysobactin
NO20090269L (no) Fenolpentadienoylderivater og deres anvendelse som PAR-1-antagonister
DK1784403T3 (da) Pyrrolo[3,2-b]pyridinderivater samt fremgangsmåder til deres fremstilling
EA201290535A1 (ru) Способ получения фармацевтических соединений и промежуточных соединений
HK40055110A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors